Meanwhile, the off-label use of semaglutide and tirzepatide should be avoided in T1D patients at increased risk for gastroparesis (such as those with diabetic gastrointestinal autonomic neuropathy) [217], in patients with (or at risk for) restrictive eating behaviors (as it has been suggested by the case published by Seetharaman and Cengiz) [139], and in patients with “diabulimia”, a term indicating an eating disorder experienced by T1D patients and characterized by the deliberate administration of insufficient insulin to maintain glucose control for the purpose of weight loss [218,219]. This evidence concerns the gene INS and type 1 diabetes mellitus.